Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treated with sinus surgery when refractory to medical intervention. However, recurrence postsurgery is common. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor for interleukin 4 (IL‐4) and IL‐13, key and central drivers of type 2 inflammation. We report the efficacy of dupilumab in patients with CRSwNP from the SINUS‐24/SINUS‐52 trials (NCT02912468/NCT02898454), by number of prior surgeries and time since last surgery.

[1]  I. Pavord,et al.  Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE , 2020 .

[2]  I. Hussain,et al.  Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis , 2020, American Journal of Clinical Dermatology.

[3]  C. Bachert,et al.  Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications. , 2020, The journal of allergy and clinical immunology. In practice.

[4]  C. Bachert,et al.  Dupilumab Reduces Blood, Urine, and Nasal Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyps in the Phase 3 SINUS-52 Trial , 2020 .

[5]  D. Wang,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps 2020. , 2020, Rhinology.

[6]  S. Fujieda,et al.  Dupilumab: Basic aspects and applications to allergic diseases. , 2020, Allergology international : official journal of the Japanese Society of Allergology.

[7]  C. Bachert,et al.  Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper , 2020, Clinical and Translational Allergy.

[8]  A. Murphy,et al.  Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.

[9]  S. Nguyen,et al.  Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta‐analysis of risk factors , 2019, International forum of allergy & rhinology.

[10]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[11]  C. Bachert,et al.  The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. , 2019, Rhinology.

[12]  M. Varacallo,et al.  2019 , 2019, Journal of Surgical Orthopaedic Advances.

[13]  Claus Bachert,et al.  Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement , 2018, International forum of allergy & rhinology.

[14]  C. Rumeau,et al.  Updating nasalisation: From concept to technique and results. , 2018, European annals of otorhinolaryngology, head and neck diseases.

[15]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[16]  M. Rogers,et al.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study , 2017, British Medical Journal.

[17]  L. Rudmik,et al.  Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis , 2017, The Laryngoscope.

[18]  R. Lockey,et al.  Cross-talk between human mast cells and epithelial cells by IgE-mediated periostin production in eosinophilic nasal polyps. , 2016, The Journal of allergy and clinical immunology.

[19]  R. Sacks,et al.  Clinical implications of mucosal remodeling from chronic rhinosinusitis , 2016, International forum of allergy & rhinology.

[20]  C. Bachert,et al.  Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. , 2016, The Journal of allergy and clinical immunology.

[21]  W. Fokkens,et al.  International Consensus Statement on Allergy and Rhinology: Rhinosinusitis , 2016, International forum of allergy & rhinology.

[22]  G. Yancopoulos,et al.  Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.

[23]  C. Hopkins,et al.  Surgical Versus Medical Interventions in CRS and Nasal Polyps: Comparative Evidence Between Medical and Surgical Efficacy , 2015, Current Allergy and Asthma Reports.

[24]  T. Morikawa,et al.  Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study , 2015, Allergy.

[25]  A. Kato.  Immunopathology of chronic rhinosinusitis. , 2015, Allergology international : official journal of the Japanese Society of Allergology.

[26]  R. Orlandi,et al.  Investigation of change in cardinal symptoms of chronic rhinosinusitis after surgical or ongoing medical management , 2015, International forum of allergy & rhinology.

[27]  C. Hopkins,et al.  Surgical interventions for chronic rhinosinusitis with nasal polyps. , 2014, The Cochrane database of systematic reviews.

[28]  L. Macdonald,et al.  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.

[29]  F. Alt,et al.  Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes , 2014, Proceedings of the National Academy of Sciences.

[30]  W. Hosemann,et al.  Danger points, complications and medico-legal aspects in endoscopic sinus surgery , 2013, GMS current topics in otorhinolaryngology, head and neck surgery.

[31]  S. Vlaminck,et al.  The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study , 2013, Clinical and Translational Allergy.

[32]  A. Peters,et al.  Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. , 2013, American journal of respiratory and critical care medicine.

[33]  B. Rotenberg,et al.  Revision Rates after Endoscopic Sinus Surgery: A Recurrence Analysis , 2011, The Annals of otology, rhinology, and laryngology.

[34]  C. Bachert,et al.  Oral steroids and doxycycline: two different approaches to treat nasal polyps. , 2010, The Journal of allergy and clinical immunology.

[35]  V. Lund,et al.  Long‐term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis , 2009, The Laryngoscope.

[36]  V. Lund,et al.  Psychometric validity of the 22‐item Sinonasal Outcome Test , 2009, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[37]  Michelle J. Thompson.  For surgeons , 2006, BMJ : British Medical Journal.

[38]  L. Kalogjera,et al.  European Position Paper on Rhinosinusitis and Nasal Polyps , 2007 .